A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) (NCT04529772)
Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Acalabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects ≤75 Years With Previously Untreated Non-GCB DLBCL
🩺 Plain-English Summary (8th-Grade Level)
Phase 3 randomized, double-blind, placebo-controlled, study assessing the efficacy and safety of acalabrutinib plus rituximab,cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) vs placebo plus R-CHOP in subjects ≤75 years of age with previously untreated non-germinal center diffuse large B-cell lymphoma.
Who can join: Review the eligibility criteria below.
Location: Research Site — Tucson, Arizona
Age range: 18 Years to 75 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (243 Sites)
Showing the first 25 of 243 sites.
- Research Site — Tucson, Arizona
- Research Site — Little Rock, Arkansas
- Research Site — Irvine, California
- Research Site — Aurora, Colorado
- Research Site — Norwich, Connecticut
- Research Site — Fort Myers, Florida
- Research Site — Orlando, Florida
- Research Site — St. Petersburg, Florida
- Research Site — Tallahassee, Florida
- Research Site — West Palm Beach, Florida
- Research Site — Fort Wayne, Indiana
- Research Site — Des Moines, Iowa
- Research Site — Wichita, Kansas
- Research Site — Louisville, Kentucky
- Research Site — Baltimore, Maryland
- Research Site — Grand Rapids, Michigan
- Research Site — Minneapolis, Minnesota
- Research Site — St Louis, Missouri
- Research Site — Albany, New York
- Research Site — New York, New York
- Research Site — New York, New York
- Research Site — Stony Brook, New York
- Research Site — Charlotte, North Carolina
- Research Site — Winston-Salem, North Carolina
- Research Site — Eugene, Oregon
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Diffuse Large B-Cell Lymphoma
- Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients — Daphne, Alabama
- A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) — Tucson, Arizona
- Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas — Birmingham, Alabama
- A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL) — Rochester, New York
- Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma — Cleveland, Ohio
Explore by condition: All Diffuse Large B-Cell Lymphoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.